ArticleAnnals of Indian Academy of Neurology2020
Consensus Statement On Immune Modulation in Multiple Sclerosis and Related Disorders During the COVID-19 Pandemic: Expert Group on Behalf of the Indian Academy of Neurology.
Article in Annals of Indian Academy of Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.Journal of neuroimmunology · 2021Review
- Can pulse steroid therapy increase the risk of infection by COVID-19 in patients with multiple sclerosis?Clinical neurology and neurosurgery · 2021Article
- COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.CNS drugs · 2021Article
- Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices.Journal of neurology · 2020Article
- Impact of COVID-19 pandemic in the activity of a Therapeutic Apheresis unit in Italy.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2020Article
- Management of Idiopathic CNS inflammatory diseases during the COVID-19 pandemic: Perspectives and strategies for continuity of care from a South East Asian Center with limited resources.Multiple sclerosis and related disorders · 2020Article
- Neurology and COVID-19: Acting now. Preparing for Future.Annals of Indian Academy of NeurologyArticle
- World Brain Day 2020 - Challenges and Opportunities in India.Annals of Indian Academy of NeurologyArticle
- Consensus Statement on Neurorehabilitation during COVID-19 Times: Expert Group on Behalf of the Indian Federation of Neurorehabilitation (IFNR).Annals of Indian Academy of NeurologyArticle
- Integration of Teleneurology within the Health System to Manage Patients of Multiple Sclerosis and Other CNS Demyelinating Disorders During COVID-19 Pandemic.Annals of Indian Academy of NeurologyArticle
- Patients with Neurological Illnesses and Their Experience During the Lockdown: A Teleinterview-based Study.Annals of Indian Academy of NeurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Knowledge related to SARS-CoV-2 or 2019 novel coronavirus (2019-nCoV) is still emerging and rapidly evolving. We know little about the effects of this novel coronavirus on various body systems and its behaviour among patients with underlying neurological conditions, especially those on immunomodulatory medications. The aim of the present consensus expert opinion document is to appraise the potential concerns when managing our patients with underlying CNS autoimmune demyelinating disorders during the current COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.